Novel pooled testing strategies can significantly increase ability to identify COVID-19 infections
SARS-CoV-2 testing is a powerful tool for curbing the COVID-19 pandemic and safely reopening schools and businesses
SARS-CoV-2 testing is a powerful tool for curbing the COVID-19 pandemic and safely reopening schools and businesses
Opaganib demonstrated dual anti-inflammatory and antiviral activity and targets a human cell component involved in viral replication
The license from ERS expands ZeClinics CRISPR IP portfolio and increases the validity and potency of zebrafish models for the drug discovery process
Catch up on part one of our exclusive webinar series to hear Dr. Frank Peacock dispel the four lies of high-sensitivity troponin
Funding of $231.8 million U.S. awarded to Ellume COVID-19 Home Test that integrates AnteoBind™ for superior sensitivity
The research brings a deeper understanding about how fructose could be linked to diabetes and obesity
International experts are joining forces to combat vaccine hesitancy by tackling its root cause
The Genedrive 96 SARS-CoV-2 kit is a simple, one-step RT-PCR test to detect SARS-CoV-2 RNA
Companion diagnostic can help guide treatment decisions in cases of NSCLC
Neuroscientists can now screen over 3,000 neurons from a NeuroHTS microplate in under 30 minutes with the ImageXpress Pico Automated Cell Imaging System
Emergency Use Listing granted to AstraZeneca and Serum Institute of India enabling global access to the vaccine
Focusing on innate immunity opens way for precision medicine approaches to AD
Company expands portfolio of SARS-CoV-2 testing solutions with rapid antigen test benchmarked against gold standard RT-PCR
Explore topics from in vitro diagnostics and advances in COVID-19 sample prep to neonatal hypocalcemia and cytotoxicity assay development
Eight-marker panel, including new long mononucleotide repeat (LMR) markers, enables broader view of mismatch repair deficiency
Increasing Portuguese market presence by enhancing sales and after-sales support networks
RHB-107 is a novel serine protease inhibitor targeting human cell factors involved in viral entry, and is therefore expected to be effective against emerging viral variants with mutations in the spike protein
Watch our curated collection of The Scientists' Channel interviews from some of the experts joining us at this year's summit